Latest Breaking News On - Immunogenicity persistence - Page 1 : comparemela.com

The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.

Comunidad autonoma de catalunaPhil dormitzerBiomedical research of the valencian communityFoundation for the promotion of healthEuropean society of clinical microbiologyLong term follow up studyTwo studiesImmunogenicity persistenceHerpes zoster subunitTwo subgroupsBiomedical researchValencian communityEuropean societyClinical microbiologyInfectious diseases global